Kornimate/medical-research-clean huggingface dataset:
comparison of the quality of recovery after cesarean section surgery

Conditions: Postoperative Recovery; Abdominal Pain; Cesarean Section

Summary: inadequate pain control after cesarean section surgery causes postpartum depression, persistent pain and delayed mother-infant bonding. the investigator's aim is to asses whether ultrasound guided transversalis fascia plane block (tfpb) or transversus abdominis plane (tap) block would improve postoperative quality of recovery and decrease postoperative opioid consumption after cesarean section surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status ii-iii * cesarean section surgery under spinal anesthesia exclusion criteria: * american society of anesthesiologists physical status iv * emergency surgery * general anesthesia * additional surgical intervention at the same session * body mass index of more than 35 kg/m2 * allergy to any study drugs * local infection at the injection site * history of drug abuse * communication problem * coagulopathy * preeclampsia and eclampsia

Keywords: cesarean section surgery postoperative recovery postoperative pain trasversalis fascia plane block transversus abdominis plane block obstetric quality of recovery 11 turkish score numeric rating scale
apremilast therapy for acute gouty arthritis

Conditions: Acute Gout

Summary: the purpose of the study is to learn about a possible new medicine, apremilast, for treating acute gout and compare how it works to indomethacin, a medication that has been used to treat gout for over 50 years. in order to learn about apremilast, half the participants in this study will receive apremilast and half the participants in this study will receive indomethacin. this study will measure the severity and duration of acute gout attacks in research participants, as well as measures of quality of life and any side effects or adverse reactions to the medication. there will be three study visits: a screening/baseline visit on day 1, a visit to evaluate response to treatment with study medication at day 7, and a follow-up visit at day 21.

withdrawn

Eligibility criteria:
inclusion criteria: * must understand and voluntarily sign the informed consent * must have the diagnosis of gout proven by identification of urate crystals from body fluids * must be male age \>18 years at the time of consent * must be able to adhere to the study visit schedule and other protocol requirements * must meet the following laboratory criteria: * hemoglobin \> 9.0 g/dl * white blood cell (wbc) count \> 3000/μl and \< 14,000/μl * platelet count \>100,000/μl * serum creatinine \< 2.0mg/dl * total bilirubin \< 2.0 mg/dl * aspartate transaminase (ast) and alanine transaminase (alt) \<1.5 x upper limit of normal * males, including those who have had a vasectomy, must agree to use barrier contraception (latex condom) when engaging in sexual activity with a female of child-bearing potential (fcbp) while on study medications and for 84 days after taking the last does of the medication exclusion criteria: * inability to provide voluntary consent * any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret the data from the study * females * systemic fungal infection * history of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment in the past 2 years * an active infection at presentation * use of any investigational medication within 4 weeks prior to start of study or 5 pharmacokinetic/pharmacodynamic half-lives, whichever is longer * any use of corticosteroids, cyclosporine, methotrexate, cyclophosphamide, azathioprine, mycophenolate within 4 weeks prior to start of study * any clinically significant abnormality on 12-lead ecg screening * malignancy or history of malignancy (except for treated and cured basal-cell skin carcinomas \> 3 years prior to screening)

Keywords: gout
food preference following bariatric surgery

Conditions: Obesity

Summary: roux-en-y gastric bypass (rygb) decreases appetite, caloric intake, glycemia, and body weight, all of which are maintained long term.it is controversial whether, after rygb, patients choose to eat less high fat and sugary foods in favor of lower energy dense alternatives. therefore the proposition to use direct measures in humans after rygb to test the hypothesis that the selection and intake of foods varying in fat content and glycemic index, as well as the pattern of ingestion within and across meals, changes in a manner that leads to beneficial outcomes on body weight.

roux-en-y gastric bypass (rygb) decreases appetite, caloric intake, glycemia, and body weight, all of which are maintained long term.it is controversial whether, after rygb, patients choose to eat less high fat and sugary foods in favor of lower energy dense alternatives. if true, this could conceivably contribute to improved glycemia and body weight. disparities among studies on food selection and intake are likely due to the almost complete reliance on self-reported food intake which is vulnerable to inaccuracy.this controversy can best be resolved by complementing existing findings with direct measures of target behaviour in humans. therefore the proposition to use direct measures in humans after rygb to test the hypothesis that the selection and intake of foods varying in fat content and glycemic index, as well as the pattern of ingestion within and across meals, changes in a manner that leads to beneficial outcomes on body weight.

Eligibility criteria:
inclusion criteria: 1. surgical and non-surgical groups: a) bariatric surgery b) controls with no history of bariatric surgery 2. independently mobile 3. capacity to consent to participate 4. \>18 years of age exclusion criteria: 1. pre-operatively: significant dysphagia, gastric outlet obstruction or anything that prevents subjects from eating a meal. 2. post-operatively: significant and persistent surgical complications or anything that prevents subjects from eating a meal. 3. systemic or gastrointestinal condition which may affect food intake or preference, including: i) pregnancy or ii) breast feeding. 4. active and significant psychiatric illness including substance misuse 5. significant cognitive or communication issues 6. medications with documented effect on food intake or food preference 7. history of significant food allergy and certain dietary restrictions 8. history of liver disease or pancreatitis 9. history of bradyarrythmia or congestive cardiac failure group) 10. use of medications with potential serious interactions with octreotide

Keywords: food preferences fat weight loss
social competence training for adolescents with borderline intellectual functioning

Conditions: Mental Disorders

Summary: emotional and behavioural problems as well as a lack of social competence are supposed to be common phenomena in adolescents with borderline intellectual functioning, consequently impairing their social and vocational integration. considering the lack of evaluated group interventions for this population, a cognitive-behavioural training is developed and its effectiveness is examined in a population of students attending special vocational schools. 77 adolescents with borderline intelligence are enrolled participated in the study. they are randomized either to the intervention group, who received 9 group sessions over a period of 3 months additionally to the standard vocational training (social competence training for adolescents with borderline intelligence, sct-abi) or to the control group who received only the standard vocational training. outcome measures at the end of the intervention and at a 6-months follow-up assessment comprise self-reports, caregiver-reports, and behavioural observations of cognitive, emotional, and behavioural factors of social competence.


Eligibility criteria:
inclusion criteria: * age 16 - 23 years * participating in special vocational training program * elevated scores in a screening measure of behavioral/emotional disorders (cbcl or ysr t\>59) exclusion criteria: * major psychiatric disorder (psychosis, major depression, substance abuse)

Keywords: adolescents borderline intellectual functioning social competence training vocational training group intervention cognitive behavioral therapy adolescents with borderline intellectual functioning
gene therapy for acm due to a pkp2 pathogenic variant

Conditions: Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC

Summary: this is a phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of lx2020 in adult patients with pkp2-acm


Eligibility criteria:
selected inclusion criteria: * adults with a clinical diagnosis of acm meeting the 2010 revised task force criteria (tfc) * genetic testing documenting a pathogenic or likely pathogenic variant in pkp2 * frequent premature ventricular complexes (pvcs) * implantable cardioverter-defibrillator (icd) implantation ≥ 12 weeks prior to the pre-screening mri * left ventricular ejection fraction ≥ 40% selected exclusion criteria: * evidence of variant(s) in addition to pkp2 that meets the standard criteria to be considered pathogenic or likely pathogenic for acm * other cardiac abnormalities as specified in the protocol * new york heart association functional class iv at the time of consent * history of prior gene transfer therapy

Keywords: arrhythmogenic cardiomyopathy acm cardiomyopathy arvc arrhythmogenic right ventricular arrhythmogenic right ventricular dysplasia genetic cardiomyopathy gene therapy pkp2 gene plakophilin-2 lx2020 heroic-pkp2 ventricular arrhythmia pvcs sudden cardiac death cardiac arrest
a safety study to evaluate the use and effectiveness of a topical ointment to treat adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to investigate the pharmacokinetics and safety of opa-15406 in adult subjects with atopic dermatitis


Eligibility criteria:
inclusion criteria: * adult subjects 18-65 years of age * diagnosis of atopic dermatitis (ad) * ad affecting at least 5% of total body surface area (bsa) for part 1 and at least 10% bsa for part 2, not including face, neck, and head * have had a positive but inadequate response to one or more treatment course of standard ad therapy including topical steroids, uv light a, narrowband uv b, and uv light b. exclusion criteria: -use of systemic or topical therapy for contact or atopic dermatitis within 30 days of screening

Keywords: atopic dermatitis, eczema
purrble's soothing touch for eating disorders and autism

Conditions: Eating Disorders; Autism Spectrum Disorder

Summary: the purpose of this study is to explore the potential therapeutic benefits of the purrble intervention, a tangible device designed to assist with in-situ emotion regulation, for individuals on the south london and maudsley nhs trust (slam) eating disorders outpatient service waiting list. by examining its effects on emotion regulation, sensory sensitivity, depression, anxiety, and motivation for treatment engagement, the study seeks to offer empirical evidence on the efficacy of the purrble as a supportive tool while patients are on the waiting list for formal outpatient treatment.


Eligibility criteria:
inclusion criteria: * currently enrolled on the south london and maudsley nhs foundation trust (slam) eating disorders outpatient service waiting list * confirmed diagnosis of an ed. * participants aged 18 and above. * willing to commit to the duration of the study and provide informed consent. exclusion criteria: * individuals currently dealing with substance abuse issues. * individuals with active psychosis. * individuals currently experiencing high suicidality or deemed to be at a high risk of self-harm. * individuals currently undergoing a separate ed treatment. * individuals who have previously been exposed to the purrble intervention.

Keywords: eating disorders autism sensory porcessing emotion regulation purrble
procalcitonin in pleural pleuritis

Conditions: Pleuritis; Pleural Empyema

Summary: the purpose of this study is to determine pleural level of procalcitonin in differents situations of pleuritis.

determine pleural level of procalcitonin in pleuritis. two periods first period evaluation in vitro study/ determine adequat technique included type of samples tubes for adequat analysis. second periods : patient with pleuritis . empyema or not

Eligibility criteria:
inclusion criteria: * pleuritis * hospitalisation exclusion criteria:

Keywords: pleuritis empyema procalcitonin
evaluating an online wellness intervention for greek adolescents

Conditions: Depressive Symptoms; Anxiety; Happiness

Summary: the investigators are evaluating the effects of an online single-session mental health intervention (the common elements toolbox; comet). to evaluate comet, the investigators are conducting a randomized controlled trial with greek adolescents attending high school in the attica region in greece. students will be randomized to the comet condition or to an active control condition. primary outcome measures (depressive symptoms, anxiety symptoms, subjective well-being) will be measured at two weeks post-intervention and four weeks post-intervention. the investigators will evaluate comet as a universal intervention (using the full sample) and as a targeted intervention (analyzing those who reported elevated depressive symptoms or anxiety symptoms at baseline).


Eligibility criteria:
inclusion criteria: * between 13 and 20 years old and a student at a participating greek high school. access to the internet.
italian study for congenital platelet disorders

Conditions: Platelet Disorder

Summary: inherited platelet disorders (ipd) are a heterogeneous group of rare bleeding diseases associated with a reduction of platelet number and/or function and with a bleeding tendency ranging from mild to severe. the frequency of inherited thrombocytopenias has been estimated to be 2.7/100,000 while the prevalence of inherited platelet function disorders is unknown, partly because they are frequently overlooked due to their difficult diagnosis.

this a no-profit national multicenter ambispectic (retrospective and prospective) observational study. after collection of informed consent form each patient, each center will enroll the patient and will collect general, laboratory and clinical data on an electronic crf on a redcap platform. each patient will receive a unique identification number. all clinical events will be reported in the data base.

Eligibility criteria:
inclusion criteria: * all patients with established diagnosis of inherited number or function platelet disorder (ipn and ipd, respectively), on the basis of internationally established clinical, laboratory and genetic criteria will be enrolled. * for patients \<18 ys, consensus will be signed by parents or legal responsible exclusion criteria: * no written consent * undocumented or uncertain diagnosis
laser acupuncture on pain, range of motion and function in patients with patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain syndrome (pfps) is among the most prevalent forms of knee discomfort. the main complaint is typically anterior knee pain, which gets worse while jumping, bending knee, going up or down stairs, or sitting for long periods of time with bent knee. teens and early adulthood are commonly affected by patellofemoral pain syndrome, with a higher frequency in females. in healthy general populations, the prevalence of patellofemoral pain syndrome is 22.7%, and in teens, it is 28.9%.

the treatment goals of patellofemoral pain syndrome are to reduce pain, increase muscle strength, increase flexibility, and correct the patellar movement tract. conservative methods should be used before invasive methods when treating pfps. one of the ways that people with pfps may benefit from improved knee function and long-term pain reduction is by strengthening their quadriceps muscles, which primarily reduce force in the patellofemoral joint. conservative methods described in the literature include the following: modifying activities; electrophysical modalities like biofeedback; therapeutic ultrasound; neuromuscular electrical stimulation; thermotherapy; interferential current; transcutaneous electrical nerve stimulation (tens); knee braces; strengthening the hamstring, anterior tibialis, and gluteal muscles; stretching for iliotibial band and lateral retinaculum.

Eligibility criteria:
inclusion criteria: * patients with patellofemoral pain syndrome (positive clarkes sign and waldron test) * age from 18 to 25 years * patients suffering from pain which aggravated by prolonged sitting, stair climbing, running, squatting, kneeling, hopping\\jumping, overuse activities and relieved by rest for at least 3 months * visual analog scale (vas) greater than 3 points in daily activity * the ability to participate in the study and follow the treatment schedule. exclusion criteria: * physiotherapy in the last 12 months * intra-articular injection in the last 3 months * other knee disorders such as: (osteoarthritis, previous knee surgery, history of knee arthroplasty, or traumatic injury related joint deformity) * bmi greater than or equal 30 * pregnancy * pacemaker insertion * photosensitivity * history of using oral analgesic or nsaids in the previous 4 weeks, * history of malignancy, psychiatric disorder, mental retardation, neurologic dysfunction, diabetes mellitus, or uncontrolled hypertension.

Keywords: laser acuouncture function pain range of motion
safety, tolerability, and efficacy of caspofungin versus amphotericin b deoxycholate in the treatment of invasive candidiasis in neonates and infants (mk-0991-064)

Conditions: Candidiasis, Invasive

Summary: the study will evaluate the safety, tolerability, and efficacy of caspofungin as compared with amphotericin b deoxycholate in the treatment of invasive candidiasis in neonates and infants. the primary hypothesis to be tested in the study is that caspofungin will be superior to amphotericin b deoxycholate with regard to the proportion of participants with fungal-free survival at the 2-week post-therapy follow-up visit.


Eligibility criteria:
inclusion criteria: * culture-confirmed invasive candida infection exclusion criteria: * candida disease limited to the oropharynx, esophagus, or other mucosal or superficial skin surfaces * positive culture for candida only from sputum, broncho-alveolar lavage, catheter tip, or previously placed indwelling non-vascular catheters or drains * prosthetic device as the suspected site of candida infection * active co-infection with a non-candida fungal organism * received \>48 hours of systemic antifungal treatment since the positive candida index culture was collected as therapy for the present episode of invasive candidiasis * failed prior systemic antifungal therapy for the present episode of invasive candidiasis * diagnosis of acute hepatitis or cirrhosis * scheduled or anticipated to receive rifampin or other systemic antifungal therapy while on study therapy * history (including participant's mother) of allergy, hypersensitivity, or any serious reaction to caspofungin or other member of the echinocandin class, or to amphotericin b deoxycholate or other member of the polyene class * severe congenital disorder known to lower immune response
effect of using whey protein and creatine supplements on muscular strength in weight-training adult males

Conditions: Nutritional Status

Summary: the purpose of this study was to evaluate the effect of combined whey protein and creatine supplement, as compared with whey protein supplement alone, on change in upper and lower body strength.


Eligibility criteria:
inclusion criteria: * recreationally active males * age 18 to 35 years * bmi 19 to 29.9 kg/m2 * weight training 3 to 4 times a week for at least 6 months before the trial exclusion criteria: * participants with medical conditions including active heart disease, high blood pressure, renal or hepatic impairment type i or ii diabetes, bipolar disease, pulmonary disease, thyroid disease, immune disorder, psychiatric disorder * dietary or herbal supplement used in the past 60 days to increase muscle mass * use of protein supplement in the past 7 days * use of thermogenic supplement or beverage in the past 7 days * use of non-steroidal anti inflammatory drugs or corticosteroids in the past 7 days
fructose supplementation in carriers for hereditary fructose intolerance

Conditions: Hereditary Fructose Intolerance

Summary: this study aimed to examine metabolic response to a short-term fructose enriched diet in carriers for hereditary fructose intolerance compared to controls. effects of fructose coffees will be assessed in 7 healthy volunteers and 7 subjects with heterozygous mutation for aldob gene in a randomized, controlled, crossover trial.

a high fructose intake also increases blood lactate and uric acid concentrations. it has been proposed that uric acid may contribute to insulin resistance by impairing endothelium-dependent vasodilation, promoting pro-inflammatory effects and dyslipidemia by activating de novo lipogenesis. these consequences of fructose overconsumption may be even more marked in individuals with hereditary alterations in fructose metabolism. indeed, individuals with hereditary fructose intolerance (hfi), due to biallelic mutations in the gene coding for aldolase b (aldob), may develop acute, life-threatening manifestations when exposed to fructose. heterozygous carriers of aldob mutation are quite common in the general population, with a predicted frequency ranging between 1:55 and 1:120. few studies have examined the effect of fructose ingestion in heterozygotes subject for hfi. heterozygous carriers are generally considered to have normal fructose metabolism since a \~ 50% level of aldolase b activity is presumed to be sufficient for adequate function. however, heterozygous carriers were reported to have enhanced uric acid responses to large intravenous and/or oral fructose loads. investigators hypothesized that heterozygous carriers may also have mild defects of fructose metabolism and/or a larger increase in cardiometabolic risk factors than the normal population after ingestion of moderate amounts of fructose.

Eligibility criteria:
inclusion criteria: * case subjects: heterozygous carriers for aldob mutation confirmed by molecular analysis * control subjects: healthy individuals matched for weight and age to subjects exclusion criteria: * fasting glucose \> 7.0 mmol/l * fasting triglycerides \> 4.0 mmol/l * chronic renal insufficiency (egfr \< 50 ml/min) * drugs * women who are pregnant or breast feeding * for women: lack of safe contraception * alcool consumption \> 30g/d * inability to discern

Keywords: fructose uric acid glucose homeostasis